- Home
- TLSI vs MXCT Comparison
TLSI vs MXCT Comparison
Compare TLSI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- MXCT
- Stock Information
- Founded
- TLSI 2010
- MXCT 1999
- Country
- TLSI United States
- MXCT United States
- Employees
- TLSI N/A
- MXCT N/A
- Industry
- TLSI Medical Specialities
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TLSI Health Care
- MXCT Health Care
- Exchange
- TLSI Nasdaq
- MXCT Nasdaq
- Market Cap
- TLSI 150.0M
- MXCT 148.2M
- IPO Year
- TLSI N/A
- MXCT 2021
- Fundamental
- Price
- TLSI $5.05
- MXCT $1.40
- Analyst Decision
- TLSI Strong Buy
- MXCT Buy
- Analyst Count
- TLSI 5
- MXCT 4
- Target Price
- TLSI $10.90
- MXCT $7.50
- AVG Volume (30 Days)
- TLSI 112.5K
- MXCT 1.1M
- Earning Date
- TLSI 08-12-2025
- MXCT 11-05-2025
- Dividend Yield
- TLSI N/A
- MXCT N/A
- EPS Growth
- TLSI N/A
- MXCT N/A
- EPS
- TLSI N/A
- MXCT N/A
- Revenue
- TLSI $35,990,000.00
- MXCT $35,754,000.00
- Revenue This Year
- TLSI $56.79
- MXCT N/A
- Revenue Next Year
- TLSI $54.15
- MXCT $14.79
- P/E Ratio
- TLSI N/A
- MXCT N/A
- Revenue Growth
- TLSI 45.50
- MXCT N/A
- 52 Week Low
- TLSI $3.42
- MXCT $1.26
- 52 Week High
- TLSI $5.88
- MXCT $5.20
- Technical
- Relative Strength Index (RSI)
- TLSI 55.11
- MXCT 37.34
- Support Level
- TLSI $4.80
- MXCT $1.32
- Resistance Level
- TLSI $5.24
- MXCT $1.44
- Average True Range (ATR)
- TLSI 0.35
- MXCT 0.06
- MACD
- TLSI 0.02
- MXCT 0.03
- Stochastic Oscillator
- TLSI 72.18
- MXCT 53.12
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.